Results 71 to 80 of about 648,282 (342)

Impact of Asymptomatic Intracranial Hemorrhage on Outcome After Endovascular Stroke Treatment

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Endovascular treatment (EVT) achieves high rates of recanalization in acute large‐vessel occlusion (LVO) stroke, but functional recovery remains heterogeneous. While symptomatic intracranial hemorrhage (sICH) has been well studied, the prognostic impact of asymptomatic intracranial hemorrhage (aICH) after EVT is less certain ...
Shihai Yang, Chengsong Yue, Zhuang Li, Xiaolei Shi, Haoxuan Zhu, Jie Yang, Linyu Li, Jiaxing Song, Shitao Fan, Gaoming Li, Wenzhe Sun, Zhixian Ye, Jiacheng Huang, Dahong Yang, Jinfu Ma, Xu Xu, Zhixi Wang, Lilan Wang, Guojian Liu, Fengli Li, Changwei Guo, Li Qi, Wenjie Zi   +22 more
wiley   +1 more source

The long-term impact of folic acid in pregnancy on offspring DNA methylation : follow-up of the Aberdeen folic acid supplementation trial (AFAST) [PDF]

, 2018
Funding This work was supported by the NIHR Bristol Biomedical Research Centre at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol.
Atkinson, Charlotte, Bhattacharya, Sohinee, Campbell, Doris, Gaunt, Tom, Hall, Marion, Herbert, Georgia, Kazmi, Nabila, McArdle, Wendy, Ness, Andy, Relton, Caroline L., Richmond, Rebecca C., Ring, Susan, Sharp, Gemma C., Smith, George Davey, Taylor, Caroline   +14 more
core   +3 more sources

Improvements in Health‐Related Quality of Life With Treat‐to‐Target Urate‐Lowering Therapy in Gout: A Post Hoc Analysis of a Randomized Multicenter Trial

Arthritis Care &Research, EarlyView.
Objective Although treat‐to‐target urate‐lowering therapy (ULT) is endorsed as best practice in gout management, limited data exist on its impact on health‐related quality of life (HRQoL). We assessed the impact of treat‐to‐target ULT on HRQoL among participants receiving protocolized gout care, identifying factors associated with HRQoL and HRQoL ...
Austin Barry, Bryant R. England, Harlan Sayles, Lindsay N. Helget, Maria Androsenko, Hongsheng Wu, Kaleb Michaud, Bridget Kramer, Jeff A. Newcomb, Mary T. Brophy, Anne Davis‐Karim, Ryan Ferguson, Michael H. Pillinger, Tuhina Neogi, Paul M. Palevsky, James R. O'Dell, Ted R. Mikuls   +16 more
wiley   +1 more source

Clinical response to placebo botulinum toxin injection in cervical dystonia—a systematic review and meta-analysis

Dystonia
BackgroundCervical dystonia is the most common form of focal dystonia and is the most studied neurological condition in patients receiving botulinum toxin.
Emma Wetmore, Henry Roberts, Alicia A. Livinski, Terance Camacho, Chyanne Eaton, Gina Norato, Mark Hallett, Mark Stacy   +7 more
doaj   +1 more source

The placebo effect revisited – author response

Scandinavian Journal of Work, Environment & Health, 2012
Our randomized controlled trial showed a reduction of neck/shoulder pain and headache in response to 10 weeks of resistance training performed for 2 minutes a day (1, 2).
Lars L Andersen
doaj   +1 more source

Increasing effort without noticing: A randomized controlled pilot study about the ergogenic placebo effect in endurance athletes and the role of supplement salience. [PDF]

PLoS ONE, 2018
PurposePrevious research shows that endurance performance can be enhanced by placebo ergogenic aids. This study investigates the ergogenic placebo response, which we define as an increase in objective and physiological effort without an increase in ...
Ellen K Broelz, Sebastian Wolf, Patrick Schneeweiss, Andreas M Niess, Paul Enck, Katja Weimer   +5 more
doaj   +1 more source

Individual heat map assessments demonstrate vestronidase alfa treatment response in a highly heterogeneous mucopolysaccharidosis VII study population. [PDF]

, 2019
Mucopolysaccharidosis (MPS) VII is an ultra-rare, progressively debilitating, life-threatening lysosomal disease caused by deficiency of the enzyme, β-glucuronidase. Vestronidase alfa is an approved enzyme replacement therapy for MPS VII. UX003-CL301 was
Bauer, Mislen, Chen, Chao-Yin, Cimms, Tricia, Haller, Christine, Harmatz, Paul, Song, Wenjie, Wang, Raymond Y, Whitley, Chester B   +7 more
core   +1 more source

Pharmacogenomics and the Placebo Response [PDF]

ACS Chemical Neuroscience, 2018
There is perhaps no more important time in the history of placebos to consider their role in clinical trials and in medicine. Increasingly well-designed pharmaceutical and academic clinical trials testing promising and established drug and surgical interventions have failed to "beat" the placebo response.
Kathryn T, Hall, Joseph, Loscalzo, Ted, Kaptchuk   +2 more
openaire   +2 more sources

Cost‐Effectiveness of Low‐Dose Colchicine Prophylaxis When Starting Allopurinol Using the “Start‐Low Go‐Slow” Approach for Gout: Evidence From a Noninferiority Randomized Double‐Blind Placebo‐Controlled Trial

Arthritis Care &Research, EarlyView.
Objective The aim of this study was to investigate the cost‐effectiveness of low‐dose colchicine prophylaxis for preventing gout flares when starting allopurinol using the “start‐low go‐slow” approach. Methods Participants with gout, fulfilling the American College of Rheumatology recommendations for starting urate‐lowering therapy and with serum urate
Yana Pryymachenko, Ross Wilson, Nicola Dalbeth, J. Haxby Abbott, Lisa Stamp   +4 more
wiley   +1 more source

Ultra-overt therapy: a novel medical approach centered on patient consciousness

Frontiers in Integrative Neuroscience
Within the realms of human and artificial intelligence, the concepts of consciousness and comprehension are fundamental distinctions. In the clinical sphere, patient awareness regarding medication and its physiological processes plays a crucial role in ...
Kamran Shirbache, Amirreza Liaghat, Sanam Saeifar, Ahmadreza Nezameslami, Ali Shirbacheh, Hamid Nasri, Hamidreza Namazi   +6 more
doaj   +1 more source